Literature DB >> 17502734

Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.

Constance Delaugerre1, Dominique Mathez, Gilles Peytavin, Huguette Berthé, Kivan Long, Tatiana Galperine, Pierre de Truchis.   

Abstract

In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17502734     DOI： 10.1097/QAD.0b013e32810fd744

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  8 in total

1.  GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.

Authors:  Nicole S Delino; Manabu Aoki; Hironori Hayashi; Shin-Ichiro Hattori; Simon B Chang; Yuki Takamatsu; Cuthbert D Martyr; Debananda Das; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

Authors:  G Sterrantino; M Zaccarelli; G Colao; F Baldanti; S Di Giambenedetto; T Carli; F Maggiolo; M Zazzi
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

3.  Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.

Authors:  Madhavi Kolli; Eric Stawiski; Colombe Chappey; Celia A Schiffer
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

4.  Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Authors:  Sidonie Lambert-Niclot; Philippe Flandre; Ana Canestri; Gilles Peytavin; Christine Blanc; Rachid Agher; Cathia Soulié; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

5.  C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.

Authors:  Manabu Aoki; Hironori Hayashi; Ravikiran S Yedidi; Cuthbert D Martyr; Yuki Takamatsu; Hiromi Aoki-Ogata; Teruya Nakamura; Hirotomo Nakata; Debananda Das; Yuriko Yamagata; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

6.  Profile of darunavir in the management of treatment-experienced HIV patients.

Authors:  Cameron Wolfe; Charles Hicks
Journal:  HIV AIDS (Auckl)       Date:  2009-09-29

7.  A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort.

Authors:  Hélène Chaussade; Camille Tumiotto; Fabien Le Marec; Olivier Leleux; Lucile Lefèvre; Estibaliz Lazaro; Marie-Edith Lafon; Elsa Nyamankolly; Pierre Duffau; Didier Neau; Pantxika Bellecave; Fabrice Bonnet
Journal:  Open Forum Infect Dis       Date:  2020-11-19       Impact factor: 3.835

8.  Combating HIV resistance - focus on darunavir.

Authors:  Cécile L Tremblay
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.